Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | CTSA | P10619 | 17/20 | 0.47 |
| ▸ | ACP3 | P15309 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30186780 | 0.86 | FFAR1 (0.45) | FFAR1CTSA | |
| SCHEMBL4582311 | 0.85 | FFAR1 (0.42) | FFAR1CTSA | |
| SCHEMBL12329342 | 0.85 | NR3C2 (0.42) | CTSAACP3 | |
| SCHEMBL2794839 | 0.84 | CTSA (0.49) | CTSAACP3 | |
| SCHEMBL16232166 | 0.83 | NR3C2 (0.41) | CTSAACP3 | |
| SCHEMBL363392 | 0.83 | NR3C2 (0.47) | CTSAACP3 | |
| SCHEMBL658439 | 0.82 | GABBR2 (0.48) | CTSAACP3 | |
| SCHEMBL30781885 | 0.82 | GABBR2 (0.48) | CTSAACP3 | |
| SCHEMBL106542 | 0.81 | NR3C2 (0.40) | CTSAACP3 | |
| SCHEMBL20534750 | 0.81 | CYP1A2 (0.43) | CTSAACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210040049-A1 | ANTI-HCMV COMPOSITIONS AND METHODS | EVRYS BIO, LLC (US) | 2021-02-11 | — | — | US | disclosed |
| EP-3609869-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | Bayer Aktiengesellschaft (DE) | 2020-02-19 | — | — | EP | disclosed |
| WO-2018189011-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2018-10-18 | — | — | WO | disclosed |
| US-20180170884-A1 | ANTI-HCMV COMPOSITIONS AND METHODS | FORGE LIFE SCIENCE, LLC | 2018-06-21 | — | — | US | disclosed |
| WO-2016077240-A2 | ANTI-HCMV COMPOSITIONS AND METHODS | FORGE LIFE SCIENCE, LLC (US) | 2016-05-19 | — | — | WO | disclosed |
| US-20140336198-A1 | Amine Derivatives as Potassium Channel Blockers | MERCK PATENT GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| US-20140336198-A1 | Amine Derivatives as Potassium Channel Blockers | MERCK PATENT GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BENDER STEVEN LEE (US) | 2004-05-13 | — | — | US | disclosed |
| US-6635641-B2 | For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis | AGOURON PHARMACEUTICALS, INC. | 2003-10-21 | — | — | US | disclosed |
| EP-1252146-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2001053274-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | FFAR1 1611/4885CTSA 1311/4885ACP3 436/4885 |
| US-20210040049-A1 | ANTI-HCMV COMPOSITIONS AND METHODS | RPL35, RPL7, RPL5 | FFAR1 4742/4885CTSA 51/4885ACP3 1111/4885 |
| US-20180170884-A1 | ANTI-HCMV COMPOSITIONS AND METHODS | RPL35, RPL7, RPL5 | FFAR1 4742/4885CTSA 51/4885ACP3 1111/4885 |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | FFAR1 1611/4885CTSA 1311/4885ACP3 436/4885 |
| US-20140336198-A1 | Amine Derivatives as Potassium Channel Blockers | KCNA3, KCNH3, KCNK3 | FFAR1 2942/4885CTSA 1454/4885ACP3 3842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.